Navigation Links
University Health Industries Launches Natural Pet Health Care Division
Date:6/30/2008

University Health Industries Inc., (OTCBB:UVHI) a Florida corporation engaged in the development, marketing and sale of proprietary, patent-pending nutraceutical products, including its leading brands Arthroleve(TM) and Zenstral PMS(TM), announced today that it is launching a new pet health care division.

BOCA RATON, Fla. (Business Wire EON) June 30, 2008 -- The pet health care division is designed to expand University Health Industries' current market focus on human health into the pet health care market. The American Pet Product Manufactures Association (APPMA) estimates 2008 sales to be $10.3 billion for pet supplies and OTC medicines.

The lead product will be a pet formulated version of UHI's popular and successful Arthroleve™ product for joint health and arthritis, which will be designed with a dosage and delivery system specific to canines. Small animal veterinary analgesics has been one of the fastest growing segments of the pet health care market in the last ten years, since the launch of the non-steroidal anti-inflammatory drug (NSAID) Rimadyl® in 1996. Due to concerns over side effects associated with NSAIDS, many consumers choose to try nutraceutical products first. Currently, the canine joint health market is led primarily by glucosamine/chondroitin containing products including SynoviCare® and Cosequin®. UHI's adaptation of Artholeve™ for the canine market will allow us to offer consumers a unique patent-pending formulation with clinically-proven ingredients.

Dean Peloso, Chief Executive Officer of University Health Industries, was quoted as saying, "UHI's overall strategy has always included pet health care and we are excited about beginning the process of moving this forward. This new division complements the Company's current offerings in both its human health and environmental products."

University Healt
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. University of Iowa professor identifies new eating disorder
2. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
4. Tulane University to receive $14M for international HIV/AIDS program
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. Boston University School of Medicine researcher recipient of Memory Ride Grant
7. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
8. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
9. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 University Health Industries Launches Natural Pet Health Care Division 
University Health Industries Launches Natural Pet Health Care Division
(Date:8/29/2008)...nancial implications of SSDI benefits, online fina...h disabilities. , Bellevi...to move forward after a diagnosis of a long-term d... that individuals do as much as they can to unders.../www.allsup.com/ [Allsup], which represents peopl...
(Date:8/28/2008)... - Nine new Centers opened to date in 2008 VAN...al Corporation,(CRM:TSX-V) announced today unaudit... 30, 2008 (all figures are in US dollars). Revenue...d 138% to $1,653,891 compared to,$695,994 for the ...ded June,30, 2008 increased 150% to $3,001,333 com...
(Date:8/28/2008)...ecially for the impaired, study says , ,... says that 13 percent of American seniors suffer m... University of Chicago researchers said the chief ...dvantage of financially (3.5 percent), and physica...niors with physical impairments were most likely t...
(Date:8/28/2008)... Guava Technologies, Inc.,announced the commenceme...ovide drug discovery researchers with an automated...e agreement is a key component of a larger,strateg...e is a direct,response to a voiced need for sophis... throughput research in a compact, automated, and ...
Breaking Medicine News(10 mins):Health News:Social Security Disability Can Be Key to Financial Future 2Health News:Social Security Disability Can Be Key to Financial Future 3Health News:Social Security Disability Can Be Key to Financial Future 4Health News:Social Security Disability Can Be Key to Financial Future 5Health News:Social Security Disability Can Be Key to Financial Future 6Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:13% of Seniors Report Being Mistreated 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3
...the celebration of Mother’s day reveals a sad pict...g to the statistics released by UNICEF// in India ... compared to the world scenario this accounts to m... India for every 100 000 live births there are abo...
...edical students across the country shows the angui...e country against the government's policy for rese...cal colleges, IITs or IIMs. // The protests are g...edicos the IIT students also have decided to join ...
...Service for Wales (NPHS) has announced that the ac...y rare after a caseworker was apparently diagnosed...0 patients in Gwynedd are to be screened for the v...risk to patients and is preparing a comprehensive ...
...re urged by the experts to concentrate on organic ...les, which has been alarmingly dropping due to the...Swiss and Indian experts who have just ended their...te to raise awareness about the need for adopting ...
Other Medicine News:Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 2Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 3Health News:Merciless Lathi Charge of our Meritorious Medicos 2Health News:Organic Farming May Increase The Output Of Apples In Himachal 2
(Date:8/27/2008)..., from BLISS-52 trial, expected by mid-2009 - - D...by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswi...aq: HGSI ) today announced it has completed enrol...f two pivotal Phase 3,randomized clinical trials o...ive systemic lupus erythematosus (SLE). Belimumab ...
(Date:8/26/2008)...ents can drive safely six weeks following surgical...SNewswire/ -- Six weeks following,bunion surgery, ...e able to,get back behind the wheel of a car again...e Journal of Bone and Joint Surgery ( http://www.j...sponse in patients who underwent a,first metatarsa...
(Date:8/26/2008)...ewswire/ -- Omeros Corporation today announced the... trial investigating,OMS103HP in arthroscopic ante...y. OMS103HP is an investigational drug product tha... is designed to improve postoperative,knee functio...patients an,earlier return to work. The article ti...
(Date:8/25/2008)...g. 25 /- Anthera Pharmaceuticals,Inc....oping,anti-inflammatory drugs, today announced the...coronary events with Near-term Cardiovascular,Infl...xamine the impact of,varespladib when administered...Syndrome (ACS) event., The FRANCIS trial is desig...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Braking After Bunion Surgery 2Braking After Bunion Surgery 3Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Shaking may cause brain damage and serious long term effects to infants 1376 1Shaking may cause brain damage and serious long term effects to infants 1376 2American College of Physicians publishes The Fenway Guide to LGBT Health 1374 1American College of Physicians publishes The Fenway Guide to LGBT Health 1374 2IMPACT initiative looks to improve patient participation in clinical trials 1372 1IMPACT initiative looks to improve patient participation in clinical trials 1372 2New genetic research into nicotine addiction shows promise for personalized treatment 421 1New genetic research into nicotine addiction shows promise for personalized treatment 421 2
...esented at ASCO with cediranib - a selective,VEGF ...ents alive,and progression- free at six months(1),...he,investigational agent cediranib (AZD2171) were ...can Society of Clinical Oncology,(ASCO) from a stu...an invasive form of brain tumor with a high unmet ...
...atients With Follicular Lymphoma Reported,Today at.../PRNewswire/ -- GlaxoSmithKline plc,announced toda... a,single one-week course of frontline treatment w... and Iodine I-131 Tositumomab) in,76 patients with...,lymphoma (NHL). This regimen was found to induce ...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens.
The Directigen™ Meningitis Individual Tests are presumptive latex slide agglutination tests for the direct qualitative detection of antigens to H. influenzae type b, S. pneumoniae, N. meningitid
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease).
The AP250 Auto Projector is a remote-controlled, programmable, random-access, high-resolution, ophthalmic projector.
Medicine Products: